Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771
Launched by WOCKHARDT · Nov 28, 2022
Trial Information
Current as of January 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have a Body Mass Index (BMI) between 18 and 32 (both inclusive), calculated as weight in kg/height in m2
- • Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations and ECG recordings
- Exclusion Criteria:
- • Known hypersensitivity or idiosyncratic reaction to quinolones or any other related drugs
- • Any history or evidence of disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system
- • Use of any prescription drug within 14 days prior to start of the study (check-in) and nonprescription drug within 7 days prior to start of study (check-in)
Trial Officials
Ashima Bhatia, MD
Study Director
Wockhardt Ltd
About Wockhardt
Wockhardt is a global pharmaceutical and biotechnology company headquartered in India, renowned for its innovative research and development in the fields of human health and biopharmaceuticals. With a focus on delivering high-quality, affordable medications, Wockhardt specializes in a wide range of therapeutic areas, including antibiotics, vaccines, and biotechnology-derived products. The company is committed to advancing medical science through rigorous clinical trials, ensuring the efficacy and safety of its products while adhering to the highest regulatory standards. Wockhardt's dedication to improving patient outcomes and enhancing healthcare accessibility positions it as a key player in the global pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials